Ali-Ahmad HM et al. Pertuzumab plus trastuzumab (P+T) in patients (pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. ASCO 2021;Abstract 5508.
André T et al. Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study. ESMO 2022;Abstract 549P.
Casablanca Y et al. Improving risk assessment for metastatic disease in endometrioid endometrial cancer patients using molecular and clinical features: An NRG oncology/gynecologic oncology group study. Cancer (Basel) 2022;14(17):4070. Abstract
Dou Y et al. Proteogenomic characterization of endometrial carcinoma. Cell 2020;180(4):729-48.e26. Abstract
Grushko TA et al. Effects of slide storage on detection of molecular markers by IHC and FISH in endometrial cancer tissues from a clinical trial: An NRG oncology/GOG pilot study. Appl Immunohistochem Mol Morphol 2022;30(1):27-35. Abstract
Maio M et al. Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial. ESMO 2022;Abstract 113P.
Makker V et al. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification. ASCO 2022;Abstract 5511.
Makker V et al. Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775. ESMO 2022;Abstract 525MO.
Merritt MA et al. Sex hormones, insulin, and insulin-like growth factors in recurrence of high-stage endometrial cancer. Cancer Epidemial Biomarkers Prev 2021;30(4):719-26. Abstract
O’Malley D et al. Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158. ESMO 2022;Abstract 546P.
O’Malley DM et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: Results from the KEYNOTE-158 study. J Clin Oncol 2022;40(7):752-61. Abstract
Oaknin A et al. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. ASCO 2022;Abstract 5509.
Oaknin A et al. Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study. ESMO 2022;Abstract 547P.
Tinker A et al. Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study. ESMO 2022;Abstract 548P.